Direct-to-Consumer Genetic Testing: Impending Value and the Path Forward

As medical and health information access increases exponentially, we, as individuals and patients, have become much more proactive about our health. Technology has both enabled both access and analyses, which reveal new information. Rapid advances in genomics research and the commercialization of direct-to-consumer genetic testing products have allowed patients access to genetic information without necessarily involving a medical professional or insurance company. Genetic testing has  informed people about the probable meaning and predisposition of their genetic makeup. However, consumers are vulnerable to being deluded by the results of unproven or invalid tests without guidance from a medical professional. Furthermore, as genetic testing becomes more affordable and accessible, how and/or will other technologies, such as AI, utilize these results to provide better healthcare? What is the benefit of personal genomic testing?  Can this knowledge actually change patient behavior? What is the charter of the medical community, providers, and data scientists?  Are they/we on the same plate?  Will this new era of technological medicine improve our behavior, health, and thus, health outcomes? Join us as our expert panel takes a provocative and deep dive.

Moderated by: Geetha Rao

• Geetha Rao, PhD, CEO & Co-Founder, Springborne Life Science
• Michael Snyder, PhD, Professor and Chair of Genetics, Stanford Center for Genomics and Personalized Medicine
• Ellen Berg, PhD, Chief Scientific Officer, Translational Biology for Eurofins Pharma Discovery Services
• Anita Singh, CEO, Co-Founder, GenID Solutions
• Greg Tranah, PhD, Director of Precision Medicine Research, Sutter Health CPMC Research Institute, Professor at UCSF Department of Epidemiology and Statistics